Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy (MOSAIC-TTR)
A Prospective, Longitudinal, Multi-center, Observational Study of Acoramidis In Patients With Wild-type or Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM): MOSAIC-TTR Study
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This buildup can make it harder for the heart to pump blood and may lead to worsening symptoms over time. Acoramidis is a medicine approved for the treatment of adults with wild-type or hereditary (variant) ATTR-CM. While its benefits have been demonstrated in clinical trials, more information is needed about how it is used and how patients do in everyday medical practice.
The MOSAIC-TTR study is an observational study in France. Participants will receive acoramidis as part of their usual medical care. No experimental treatments or additional medical procedures will be required. The study will collect information directly from participating hospitals and from the Healthcare European Amyloidosis Registry (HEAR; NCT05101304). The main goal of the study is to understand how patients' quality of life, daily functioning, and overall well-being change during the first 12 months of treatment with acoramidis, using questionnaires completed by the patients themselves. The study will also collect information about the characteristics of patients receiving acoramidis, how the medicine is used in routine clinical practice, and its safety and tolerability. The information collected will help improve the understanding of ATTR-CM and may help improve the care of people living with this condition.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Bayer Clinical Trials Contact
- Puhelinnumero: 4930300139003
- Sähköposti: clinical-trials-contact@bayer.com
Opiskelupaikat
-
-
-
Many Locations, Ranska
- Rekrytointi
- Many locations
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Greater than or equal to 18 years of age
- Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTR genotype
- Initiating treatment with acoramidis with the decision to treat having been made by the treating physician prior to study enrolment in accordance with the current French Summary of Product Characteristics (SmPC)
Exclusion Criteria:
- Any contraindications as listed in the local approved product information
- Prior treatment with disease-modifying treatment (e.g., tafamidis, TTR silencers and/or depleters)
- Participation in an investigational trial evaluating new Investigational Medicinal Products or new Investigational Medical Device outside of routine clinical practice
- Under legal protection (guardianship, curatorship, or other legal protection measures) or deprived of liberty by administrative or judicial decision at the time of inclusion.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Single Arm
Patients will receive acoramidis 712 mg orally BID (twice daily)
|
356 mg film-coated tablets.
The recommended dose is 712 mg (two tables, 356 mg) orally twice daily, corresponding to a total daily dose of 1424 mg.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Patient Reported Outcome Measure: Amylo-AFFECT-QOL score
Aikaikkuna: At 3, 6, 9, and 12 months after initiation of acoramidis
|
Change from baseline in Amylo-AFFECT-QOL total score
|
At 3, 6, 9, and 12 months after initiation of acoramidis
|
|
Patient Reported Outcome Measure: KCCQ-23 score
Aikaikkuna: At 3, 6, 9, and 12 months after initiation of acoramidis
|
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ-23) total score
|
At 3, 6, 9, and 12 months after initiation of acoramidis
|
|
Patient Reported Outcome Measure: EQ-5D-3L index score
Aikaikkuna: At 3, 6, 9, and 12 months after initiation of acoramidis
|
3L index score of EQ-5D Health-Related Quality of Life Questionnaire
|
At 3, 6, 9, and 12 months after initiation of acoramidis
|
|
Patient Reported Outcome Measure: EQ VAS score
Aikaikkuna: At 3, 6, 9, and 12 months after initiation of acoramidis
|
Visual Analog scale score of EQ-5D Health-Related Quality of Life Questionnaire
|
At 3, 6, 9, and 12 months after initiation of acoramidis
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Demographic characteristics: Age
Aikaikkuna: Before treatment with acoramidis
|
Age of patients initiating treatment with acoramidis
|
Before treatment with acoramidis
|
|
Demographic characteristics: Sex
Aikaikkuna: Before treatment with acoramidis
|
Sex of patients initiating treatment with acoramidis
|
Before treatment with acoramidis
|
|
Demographic characteristics: Body Mass Index
Aikaikkuna: Before treatment with acoramidis
|
Body Mass Index of patients initiating treatment with acoramidis
|
Before treatment with acoramidis
|
|
Clinical characteristics: Time between diagnosis and treatment initiation
Aikaikkuna: Before treatment with acoramidis
|
Time between ATTR-CM diagnosis and treatment initiation
|
Before treatment with acoramidis
|
|
Clinical characteristics: ATTR-CM diagnosis
Aikaikkuna: Before treatment with acoramidis
|
ATTR-CM diagnosis (genetic status including mutation type [if applicable], phenotype)
|
Before treatment with acoramidis
|
|
Clinical characteristics: ATTR-CM manifestations
Aikaikkuna: Before treatment with acoramidis
|
ATTR-CM manifestations prior to treatment initiation
|
Before treatment with acoramidis
|
|
Clinical characteristics: Comorbidities
Aikaikkuna: Up to 12 months before initiation of acoramidis, and during treatment with acoramidis
|
ATTR-CM-relevant comorbidities that were either ongoing at treatment initiation, or were previously managed or resolved in the 12 months prior to initiating acoramidis, as well as those that began after initiating acoramidis
|
Up to 12 months before initiation of acoramidis, and during treatment with acoramidis
|
|
Clinical characteristics: Prior medication and procedures
Aikaikkuna: Up to 12 months before initiation of acoramidis
|
Prior medication taken and procedures performed up to 12 months before initiation of acoramidis
|
Up to 12 months before initiation of acoramidis
|
|
Treatment patterns: Treatment duration
Aikaikkuna: During treatment with acoramidis
|
Duration of treatment with acoramidis
|
During treatment with acoramidis
|
|
Treatment patterns: Treatment interruptions
Aikaikkuna: During treatment with acoramidis
|
Proportion of patients with temporary treatment interruptions and reason for interruption
|
During treatment with acoramidis
|
|
Treatment patterns: Treatment discontinuation
Aikaikkuna: During treatment with acoramidis
|
Proportion of patients with permanent treatment discontinuation and reason for discontinuation
|
During treatment with acoramidis
|
|
Treatment patterns: Time to treatment discontinuation
Aikaikkuna: During treatment with acoramidis
|
Time to acoramidis treatment discontinuation
|
During treatment with acoramidis
|
|
Treatment patterns: Concomitant medications and procedures
Aikaikkuna: During treatment with acoramidis
|
Concomitant medications taken and procedures performed during treatment with acoramidis
|
During treatment with acoramidis
|
|
Safety and tolerability: Adverse events
Aikaikkuna: During treatment with acoramidis and up to 6 days after the last intake of acoramidis in case of premature permanent treatment discontinuation
|
Adverse events (AEs) occurring during treatment with acoramidis and AEs occurring up to 6 days after the last intake of acoramidis if premature permanent treatment discontinuation
|
During treatment with acoramidis and up to 6 days after the last intake of acoramidis in case of premature permanent treatment discontinuation
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC; ATTRibute-CM Investigators. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
- Reant P, Kharoubi M, Donal E, Bauer F, Bezard M, Bisson A, Bodez D, Bouchot O, Cariou E, Charron P, Costa J, Courand PY, Dagrenat C, Delelis F, Duval AJ, Eicher JC, Fraix A, Gellen B, Gueffet JP, Guijarro D, Habib G, Hagege A, Huttin O, Jaccard A, Jeanneteau J, Legallois D, Logeart D, Legrand L, Inamo J, Marguerit L, Mirailles R, Pezel T, Piriou N, Roubille F, Mouhat B, Tresorier R, Von Hunolstein JJ, Taieb C, Salvat M, Zaroui A, Lairez O, Damy T. The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network. Orphanet J Rare Dis. 2025 Oct 27;20(1):534. doi: 10.1186/s13023-025-04062-y.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 23181
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access.
As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .